Aurinia Pharmaceuticals Inc (AUPH)

[Pablo Bio]

The best news, if true, ((Advancing autoimmune pipeline with Phase 1 clinical program for AUR200,))

Dear Fellow Shareholders:

Aurinia’s Board of Directors and management team have been taking a range of actions to position the Company for sustainable success and build value for shareholders, while staying true to our core focus of delivering therapies to treat targeted patient populations with high unmet medical needs. We believe we have established strong momentum in the business based on recent actions to support our strategy in three key areas:

Focus on commercial execution after restructuring operations
Maximizing free cash flows, moving towards profitability, currently debt free with excess of $320M in cash, cash equivalents, restricted cash and investments
Advancing autoimmune pipeline with Phase 1 clinical program for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand)